Mode
Text Size
Log in / Sign up

Clinical pharmacist interventions reduce drug-related problems by 70.7% in adult psychiatric inpatientsPharmacists help reduce medication errors for psychiatric inpatients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider pharmacist interventions to reduce drug-related problems and medication volume in psychiatric inpatients.

This meta-analysis evaluates the impact of clinical pharmacist interventions, such as medication review, medication reconciliation, and ward round participation, on drug-related problems (DRPs) and clinical outcomes in adult psychiatric inpatients. The analysis synthesized data from 18 studies to assess medication safety and management.

Key findings include a pooled reduction of 70.7% in drug-related problems (95% CI 46.5 to 87.0) and a reduction in the number of prescribed medications by a mean difference of 1.0 medications per patient (95% CI -1.5 to -0.5). Additionally, the intervention was associated with a reduction in potentially inappropriate medications (PIMs).

Several limitations were noted, including substantial heterogeneity across the included studies. Evidence for patient-centered outcomes, such as symptom improvement, quality of life, and healthcare utilization, was limited. Furthermore, most non-randomized studies carried a serious risk of bias due to confounding and uncontrolled designs. Clinical pharmacists may improve medication safety in psychiatric settings, though evidence for broader clinical outcomes is currently insufficient.

How this fits prior evidence

This meta-analysis addresses a gap in managing medication safety for patients with mental disorders. While prior coverage noted the impact of ACEs on mental disorders and the use of AI for training, this study specifically addresses the role of pharmacist interventions in inpatient settings. It confirms that pharmacist involvement can reduce drug-related problems by 70.7% and decrease the number of prescribed medications by a mean difference of 1.0.

Managing medications in a psychiatric ward is a complex task. Patients often take multiple drugs at once, which increases the risk of errors or using medications that might not be appropriate for their specific needs. This makes the role of a clinical pharmacist vital for ensuring safety.

A review of several studies found that when pharmacists stepped in to review medications and participate in ward rounds, drug-related problems dropped by over 70 percent. They also helped reduce the total number of medications each patient received and cut down on potentially inappropriate medications.

While the results are promising for safety, the evidence is still growing. Many of the studies were not randomized, and there was less clear data on how these changes affected a patient's daily quality of life or specific symptom improvements. However, the data suggests that having a pharmacist on the team helps streamline care and reduce risks.

What this means for you:
Pharmacists in psychiatric wards can reduce drug-related problems by over 70 percent and cut unnecessary medications.

Common questions

How do pharmacists help patients in psychiatric wards?

Pharmacists provide interventions like medication reviews, reconciliation, and participating in ward rounds. These actions help reduce drug-related problems by 70.7 percent and decrease the total number of medications a patient is prescribed by an average of 1.0. They also help reduce the use of potentially inappropriate medications.

Does this help patients feel better or improve their quality of life?

The current evidence for patient-centered outcomes, such as symptom improvement or quality of life, is limited. While the study shows clear improvements in medication safety and the number of drugs prescribed, more research is needed to confirm how these changes affect a patient's daily well-being.

Is the evidence for these findings very strong?

The evidence is mixed because many of the studies were not randomized, which can lead to a risk of bias. There was also a lot of variation between the different studies included in the review. You should talk to a healthcare provider about specific treatment plans.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
IntroductionClinical pharmacist interventions have been shown to improve outcomes and reduce drug-related problems (DRPs) in patients with mental disorders. However, no previous meta-analysis has comprehensively evaluated their effectiveness in reducing DRPs and optimizing pharmacotherapy in psychiatric inpatient settings.AimTo evaluate the effectiveness of clinical pharmacist interventions in psychiatric inpatient settings on DRPs and clinical outcomes among patients with mental disorders.MethodsThis systematic review and meta-analysis was conducted according to the PRISMA 2020 statement and prospectively registered in PROSPERO (CRD420261309290). PubMed, Scopus, CENTRAL, and CINAHL were searched from inception to March 2026. Eligible studies included adult psychiatric inpatients receiving clinical pharmacist interventions, including different pharmaceutical services, such as medication review, medication reconciliation, and ward round participation. A meta-analysis was performed in R using a random-effects model. Heterogeneity was calculated using I2. Random-effects meta-analyses were performed for DRPs, potentially inappropriate medications (PIMs), and the number of prescribed medications. Risk of bias was assessed using RoB two and ROBINS-I.ResultsEighteen studies met the inclusion criteria, including one randomized controlled trial and 17 non-randomized interventional studies. Clinical pharmacist interventions significantly reduced the number of prescribed medications (mean difference −1.0 medications per patient, (95% CI −1.5 to −0.5) and were associated with a pooled reduction in DRPs of 70.7% (95% CI 46.5–87.0), as well as reductions in PIMs. Evidence for patient-centred clinical outcomes, including symptom improvement, quality of life, and healthcare utilization, remained limited. Substantial heterogeneity was observed across studies, reflecting differences in intervention types, patient populations, and outcome measures. Most non-randomized studies were judged to have a serious risk of bias because of confounding and uncontrolled study designs.ConclusionClinical pharmacist interventions in psychiatric inpatient settings improve medication-related outcomes by reducing DRPs, PIMs, and the number of prescribed medications. These findings support the integration of clinical pharmacists into multidisciplinary psychiatric teams. Further adequately powered multicentre randomized controlled trials are needed to determine whether these improvements translate into better long-term patient-centred clinical outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.